Professor, Department of Hematology & Oncology, Samsung Medical Center

Speciality Interests

Medical Oncology (Lung cancer, Head and neck cancer, Esophageal cancer)


schedule of week
07 FRI
AM available
PM available available

Medical School

Hanyang University College of Medicine

Specialty Training

Specialty Training
Fellowship   Asan Medical Center
Residency   Hanyang University Hospital
Internship   Hanyang University Hospital

Other Education

  • Master: Hanyang University Graduate School
    Ph.D: Hanyang University Graduate School
    Postdoctoral fellowship: Memorial Sloan Kettering Cancer Center, USA

Participation in Academic Societies
and Research

  • Member, Korean Medical Association
    Member, Korean Association of Internal Medicine
    Member, Korean Association of Oncology
    Member, Korean Association for Cancer Research
    Member, American Society of Oncology
    Member, International Association Society of Lung Cancer
    Member, European Society of Medical Oncology
    Member, Korean Association of Clinical Oncology
    Member, Korean Association Society of Lung Cancer
    Member, Korean Head and Neck Cancer Society


LANCET ONCOL 2019 10.1016/S1470-2045(19)30504-2

Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study

Ahn1, MJ; Han, JY; Lee, KH; Kim, SW; Kim, DW; Lee, YG; Cho, EK; Kim, JH; Lee, GW; Lee, JS; Min, YJ; Kim, JS; Lee, SS; Kim, HR; Hong, MH; Ahn, JS; Sun, JM; Kim, HT; Lee, DH; Kim, S; Cho, BC

LANCET ONCOL 2019 10.1016/S1470-2045(19)30626-6

Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial

Kato1, K; Cho, BC; Takahashi, M; Okada, M; Lin, CY; Chin, K; Kadowaki, S; Ahn, MJ; Hamamoto, Y; Doki, Y; Yen, CC; Kubota, Y; Kim, SB; Hsu, CH; Holtved, E; Xynos, I; Kodani, M; Kitagawa, Y

CANCER 2019 10.1002/cncr.32503

Epidermal growth factor receptor mutation analysis in tissue and plasma from the AURA3 trial: Osimertinib versus platinum-pemetrexed for T790M mutation-positive advanced non-small cell lung cancer

Papadimitrakopoulou1, VA; Han, JY; Ahn, MJ; Ramalingam, SS; Delmonte, A; Hsia, TC; Laskin, J; Kim, SW; He, Y; Tsai, CM; Hida, T; Maemondo, M; Kato, T; Jenkins, S; Patel, S; Huang, XN; Laus, G; Markovets, A; Thress, KS; Wu, YL; Mok, T

J THORAC ONCOL 2019 10.1016/j.jtho.2019.06.010

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC

Antonia1, SJ; Balmanoukian, A; Brahmer, J; Ou, SHI; Hellmann, MD; Kim, SW; Ahn, MJ; Kim, DW; Gutierrez, M; Liu, SV; Schoffski, P; Jager, D; Jamal, R; Jerusalem, G; Lutzky, J; Nemunaitis, J; Calabro, L; Weiss, J; Gadgeel, S; Bhosle, J; Ascierto, PA; Rebelatto, MC; Narwal, R; Liang, MN; Xiao, F; Antal, J; Abdullah, S; Angra, N; Gupta, AK; Khleif, SN; Segal, NH

J CLIN ONCOL 2019 10.1200/JCO.19.00934

Five-Year Overall Survival for Patients With Advanced Non-Small-Cell Lung Cancer Treated With Pembrolizumab: Results From the Phase I KEYNOTE-001 Study

Garon1, EB; Hellmann, MD; Rizvi, NA; Carcereny, E; Leighl, NB; Ahn, MJ; Eder, JP; Balmanoukian, AS; Aggarwal, C; Horn, L; Patnaik, A; Gubens, M; Ramalingam, SS; Felip, E; Goldman, JW; Scalzo, C; Jensen, E; Kush, DA; Hui, R


Patients' Rights and Responsibilities

Patients' Rights

1. Right to receive medical care

Patients have the right to receive proper medical and nursing services for their Health Protection and Promotion and they will not be discriminated for gender, age, religion, status, nationality, language, race, or physical/mental/financial circumstances nor be violated of their health. Medical team may not deny medical care without justifiable reason.

2. Right to be informed & autonomous decision

Patients have the right to receive be well-informed and to inquire in detail about the treating physician’s specialty, status of their disease, purpose of the treatment, treatment plan, method, expected results and side effects of the treatment, discharge plan, medical cost, whether or not they are a subject to medical research, organ transplant/donation and etc, and to decide whether to give consent. Patients may stop or deny specific treatment or planned medical care within the ethical guideline and may decide on an alternative treatment.

3. Right to have confidentiality

Patients will not be violated of their rights to confidentiality regarding their physical/health status and privacy. Medical team and facility may not reveal or announce patient’s confidential information, including personal information, unless patient has gives consent or specified in the law, such as criminal investigation.

4. Right to request for consultation and mediation

Patients may request for consultation and mediation from an internal or external agency (Korea Consumer Agency, Korea Medical Dispute Mediation and Arbitration Agency) in the event of any medical dispute.

5. Right to be respected of values or beliefs

Patients will not be discriminated for their culture, religious values or beliefs, and their rights will not be violated.

6. Right to be physically protected and to have stability of mind and bod

Patients have the right to be protected from possible danger in the hospital and to have the stability of mind and body.


1. Responsible to trust and respect the medical team

Patients must accurately inform the medical team of their health condition, trust and respect the medical team’s treatment plan. Patients may be responsible for consequences which results from not following the instruction.

2. Responsible to not use dishonest method for medical treatment

Patients must reveal their identity before receiving any medical care and must not use false or dishonest method, such as receiving medical case under disguised ownership.

3. Responsible to abide by all hospital regulations

Patients must abide by all hospital regulations, respect hospital staff and other patients, and earnestly fulfill the financial obligation to the hospital.